Study of Lipid Profile of Patients With Chronic Coronary Syndromes at Sohag University Hospital

NCT04977089 | Unknown

• 1 other identifier: Soh-Med-21-07-01
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

Chronic coronary syndrome (CCS) is a newly described classification devised by the European Society of Cardiology (ESC) 2019 to replace the term "Stable Coronary Artery Disease (CAD). The main reason for effecting the change is the term is thought to better describe the disease process and encompass a wider spectrum of clinical, pharmacological, and pathophysiological entities. Using this new term, the disease atherosclerosis manifests as CAD is categorized into Acute Coronary Syndrome (ACS) and CCS. The main focus of introducing the concept of CCS is on the fact that CAD is a continuous phenomenon involving intravascular plaque aggregation and progression which has different evolutionary phases. Dyslipidemia is recognized as a prominent risk factor for cardiovascular (CV) disease. It is characterized by an elevation of serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), or triglycerides (TG) and reduced serum high-density lipoprotein cholesterol (HDL-C) concentration . Genetically determined and metabolically induced disturbances in lipid metabolism, as manifested in several types of dyslipidemia, have been shown to be causally related to the development of coronary artery disease (CAD). A diversity of clinical and angiographic studies has been made to evaluate the linkage between plasma lipid-control therapy in the development of recurrent cardiovascular events. Independent predictors of recurrent CVD events or death include age, smoking, hypertension (HTN), dyslipidemia, diabetes mellitus, chronic kidney disease, and the underutilization of medications recommended by current treatment guidelines.

Conditions

Ischemic Heart Disease; Dyslipidemias

Outcome Measures

Primary Outcomes (1)

• Dyslipidemia in chronic coronary syndrome

  Pattern of dyslipidemia among patients with chronic coronary syndromes at sohag university hospital.

  one year

Study Arms (1)

Ischemic heart disease patients .

Study of lipid profile of patients with chronic coronary syndromes who recieve drugs of anti hyperlipidemia at the cardiology clinic of sohag university hospital.

Diagnostic Test: lipid profile test .

Interventions

lipid profile test . DIAGNOSTIC_TEST

Assesment of lipid profile of patients (cholesterol level ,TG ,VLDL )

Ischemic heart disease patients .

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

I examine cross sectional study which classify 100 patients with chronic coronary syndrome into: two main groups : * patient on statin therapy. * patient not on statin therapy. \_And determine if patints in sohag university hospital could achive the target lipid profile level of their group according to 2019 ESC/EAS Guidelines for the management of dyslipidaemia. I classify 100 patients with chronic coronary syndrome into: two main groups : * patient on statin therapy. * patient not on statin therapy. \_And determine if patints in sohag university hospital could achive the target lipid profile level of their group according to 2019 ESC/EAS Guidelines for the management of dyslipidaemia.

You may qualify if:

• All patients have chronic coronary disease at Sohag University hospital who recieve drugs of anti hyperlipidemia .

You may not qualify if:

• Patients with first attack of acute coronary syndrome .
• Young patients \<18 years .
• Old patients \>65 years.

Sponsors & Collaborators

• Sohag University: lead

Study Sites (1)

Sohag University Hospital

Sohag, Egypt

RECRUITING

Related Publications (3)

• Darroudi S, Saberi-Karimian M, Tayefi M, Arekhi S, Motamedzadeh Torghabeh A, Seyedzadeh Sani SMR, Moohebati M, Heidari-Bakavoli A, Ebrahimi M, Azarpajouh MR, Safarian M, A Ferns G, Esmaeili H, Parizadeh MR, Mokhber N, Mahdizadeh A, Mahmoudi AA, Sahebkar AH, Ghayour-Mobarhan M. Prevalence of combined and noncombined dyslipidemia in an Iranian population. J Clin Lab Anal. 2018 Oct;32(8):e22579. doi: 10.1002/jcla.22579. Epub 2018 Jun 21.

  PMID: 29926995 BACKGROUND

• Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020 Jan 14;41(3):407-477. doi: 10.1093/eurheartj/ehz425. No abstract available.

  PMID: 31504439 BACKGROUND

• Mortensen MB, Falk E, Li D, Nasir K, Blaha MJ, Sandfort V, Rodriguez CJ, Ouyang P, Budoff M. Statin Trials, Cardiovascular Events, and Coronary Artery Calcification: Implications for a Trial-Based Approach to Statin Therapy in MESA. JACC Cardiovasc Imaging. 2018 Feb;11(2 Pt 1):221-230. doi: 10.1016/j.jcmg.2017.01.029. Epub 2017 Jul 25.

  PMID: 28624395 BACKGROUND

MeSH Terms

Conditions

Myocardial Ischemia; Dyslipidemias

Condition Hierarchy (Ancestors)

Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Lipid Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases

Central Study Contacts

Islam M Farrag, resident

CONTACT

01092029333; islam010011@med.sohag.edu.eg

Ali M Ahmed, professor

CONTACT

01003459738

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: resident doctor at internal medicine department sohag university hospital

Study Record Dates

• First Submitted: July 14, 2021
• First Posted: July 26, 2021
• Study Start: August 1, 2020
• Primary Completion: August 1, 2021
• Study Completion: August 1, 2021
• Last Updated: July 26, 2021

Record last verified: 2021-07

Data Sharing

• IPD Sharing: Will share

Locations

EG (1)